Bertolini Mark T 4

What Happened
Mark T. Bertolini, CEO of Oscar Health (OSCR), sold a total of 1,238,996 shares in open-market transactions on June 29–30, 2026, generating total proceeds of about $35.77 million. The individual transactions reported were:

• 555,826 shares at $29.17 — $16,213,444 (6/29)
• 58,926 shares at $30.08 — $1,772,494 (6/29)
• 488,654 shares at $28.35 — $13,853,341 (6/30)
• 135,590 shares at $28.97 — $3,928,042 (6/30)
  These sales were reported as dispositions (S). Such sales are commonly routine (e.g., to cover taxes) rather than a buy signal.

Key Details

• Transaction dates: June 29, 2026 and June 30, 2026; Form 4 filed July 1, 2026 (appears timely).
• Total shares sold: 1,238,996; total proceeds: ~$35.77M.
• Post-transaction holdings: Not specified in the excerpt provided — see the full Form 4 for total beneficial ownership after these sales.
• Footnotes: Sales were effected to satisfy tax withholding related to deferred settlement of performance stock units that vested April 3, 2026, pursuant to a Rule 10b5-1 instruction letter entered 11/10/2025 and amended 3/24/2026. Reported prices are weighted averages; the underlying trades were executed across price ranges (roughly $27.78–$30.61 per share) as detailed in the filing. The reporting person will provide a price-by-price breakdown on request.

Context
These transactions were sales to cover tax obligations tied to vested equity (not new purchases). For retail investors, purchases or insider-initiated acquisitions often carry more interpretive weight than routine sales for tax or settlement reasons. The filing identifies a 10b5-1 plan, which indicates pre-scheduled execution rather than opportunistic trading.